- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
TROP2 Membrane Ratio Effectively Predicts Dato-DXd Outcomes in NSCLC
September 8th 2024, 11:18pm
IASLC World Conference on Lung Cancer
An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.
Dr Sen on Interim IDeate-Lung01 Data in Extensive-Stage SCLC
September 8th 2024, 10:30pm
IASLC World Conference on Lung Cancer
Triparna Sen, PhD, discusses findings from an interim analysis of the phase 2 IDeate-Lung01 trial in patients with extensive-stage small cell lung cancer.
Patient-Level Data Support Perioperative Nivolumab Use in Resectable NSCLC
September 8th 2024, 9:15pm
IASLC World Conference on Lung Cancer
Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.
Novel Perioperative Combinations Show Efficacy in Resectable NSCLC
September 8th 2024, 8:27pm
IASLC World Conference on Lung Cancer
Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.
Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC
September 8th 2024, 7:57pm
IASLC World Conference on Lung Cancer
Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.
Dr Spira on Updated MARIPOSA Trial Data in EGFR+ Advanced NSCLC
September 8th 2024, 6:25pm
IASLC World Conference on Lung Cancer
Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.
Global Survey Examines Barriers to Optimal Lung Cancer Biomarker Testing
September 8th 2024, 1:07am
IASLC World Conference on Lung Cancer
Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.
Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC
September 7th 2024, 10:37pm
IASLC World Conference on Lung Cancer
A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.
Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes
September 7th 2024, 6:14pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.
Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma
September 7th 2024, 4:52pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.
Histologic Distinctions and Optimized Imaging Carve New Paths for Individualized PTCL Management
September 7th 2024, 12:00pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.
Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma
September 6th 2024, 8:26pm
Society of Hematologic Oncology Annual Meeting (SOHO)
The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.
Dr Seymour on the Role of Mutational Profiling in CLL
September 6th 2024, 6:55pm
Society of Hematologic Oncology Annual Meeting (SOHO)
John Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia.
Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features
September 6th 2024, 6:09pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL
September 6th 2024, 5:27pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.
D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma
September 6th 2024, 4:15pm
Society of Hematologic Oncology Annual Meeting (SOHO)
D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.
Improved OS, Cost Effectiveness Are Necessary to Shift Later-Line TKIs to Frontline CML-CP
September 6th 2024, 1:00pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Elias Jabbour, MD, discusses the potential activity and financial benefit of novel and emerging TKIs for first-line management of chronic phase CML.
Dr Merryman on the Evolution of MRD Assays in Lymphoma
September 5th 2024, 7:25pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.
Dr Kebriaei on the Potential Shift Away From Transplant in ALL
September 5th 2024, 7:25pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.
Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma
September 5th 2024, 5:40pm
Society of Hematologic Oncology Annual Meeting (SOHO)
The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.